Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Plays Up Its In-house Potential, Avoids M&A Talk

Executive Summary

Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.

You may also be interested in...



Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS

Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year. 

Pfizer Remains Flexible On Consumer Health In Restructuring

The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.

Pfizer Remains Flexible On Consumer Health In Restructuring

The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel